Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
1.175
-0.075 (-6.00%)
Mar 13, 2026, 4:00 PM EDT - Market closed
Phio Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
13.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 21.00K | -117.00K | -84.78% |
| Dec 31, 2018 | 138.00K | 123.00K | 820.00% |
| Dec 31, 2017 | 15.00K | -4.00K | -21.05% |
| Dec 31, 2016 | 19.00K | -15.00K | -44.12% |
| Dec 31, 2015 | 34.00K | -37.00K | -52.11% |
| Dec 31, 2014 | 71.00K | -328.00K | -82.21% |
| Dec 31, 2013 | 399.00K | 302.00K | 311.34% |
| Dec 31, 2012 | 97.00K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curis | 11.65M |
| BioAtla | 11.00M |
| Traws Pharma | 2.85M |
| Serina Therapeutics | 116.00K |
| BioCardia | 3.00K |
PHIO News
- 3 days ago - Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT - GlobeNewsWire
- 3 days ago - Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT - Newsfile Corp
- 7 days ago - Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update - Newsfile Corp
- 8 days ago - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - Newsfile Corp
- 4 weeks ago - What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? - Benzinga
- 4 weeks ago - Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Benzinga
- 4 weeks ago - Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial - Newsfile Corp
- 6 weeks ago - Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference - Newsfile Corp